Impact of Perioperative Physical Activity on Postoperative Pulmonary Complications and Quality of Life Among Esophageal Cancer Patients

October 10, 2018 updated by: Samsung Medical Center

Impact of Perioperative Physical Activity on Postoperative Pulmonary Complications and Quality of Life Among Esophageal Cancer Patients: A Prospective Cohort Study

This prospective cohort study examines the impact of perioperative physical activity on postoperative pulmonary complications among esophageal cancer patients.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Anticipated)

180

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients who are diagnosed with eshophageal cancer and scheduled to receive curative esophagectomy at a single cancer hospital in Seoul, Korea

Description

Inclusion Criteria:

  • Patients who are diagnosed with esophageal cancer and scheduled to receive curative esophagectomy
  • Patients who are able to read and understand the questionnaire
  • Patients who are able to communicate with research personnel
  • Patients who recognize the purpose of this study and provide written informed consent
  • Patients without treatment for psychiatric disease

Exclusion Criteria:

  • Patients who have difficulty for walking
  • Patients with history of other cancer in the last 3 years
  • Patients with neoadjuvant chemotherapy and/or radiation therapy
  • Patients with recurrent esophageal cancer
  • Patients with multiple cancer
  • Foreigner or overseas patients who were not able to regularly participate this study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pulmonary complications
Time Frame: Within 30 days after surgery
Incidence of pneumonia and atelectasis
Within 30 days after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The change of quality of life
Time Frame: Before surgery(baseline), and 1, 6, 12, 24, 36, 48, and 60 months after surgery
The change of quality of life is measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) core30 (C30). The quality of life scale is transformed into a score 0 to 100, derived by 4-point Likert scale. A higher score represents a higher level of quality of life.
Before surgery(baseline), and 1, 6, 12, 24, 36, 48, and 60 months after surgery
The change of symptom
Time Frame: Before surgery(baseline), and 1, 6, 12, 24, 36, 48, and 60 months after surgery
The change of symptoms is measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) oesophageal cancer module (OES18). The symptom scale is transformed into a score 0 to 100, derived by 4-point Likert scale. A higher score represents a higher level of symptom.
Before surgery(baseline), and 1, 6, 12, 24, 36, 48, and 60 months after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Young Mog Shim, MD, Samsung Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 6, 2015

Primary Completion (Anticipated)

December 31, 2019

Study Completion (Anticipated)

December 31, 2024

Study Registration Dates

First Submitted

July 10, 2017

First Submitted That Met QC Criteria

July 26, 2017

First Posted (Actual)

July 27, 2017

Study Record Updates

Last Update Posted (Actual)

October 11, 2018

Last Update Submitted That Met QC Criteria

October 10, 2018

Last Verified

September 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • 2014-10-035

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Esophageal Neoplasms

Search Similar Trials